Description
Unnatural amino acids are increasingly growing in research stature for pharmaceuticals, food and feed additives, agrochemicals, and other industrial applications. Some amino acids such as isoleucine, threonine, and hydroxyproline, exhibit second centre of asymmetry and hence can exist in four sterioisomeric forms. The global Unnatural Amino Acids market is segmented on the basis of type, product, application, and end user.
The global unnatural amino acids market is segmented on the basis of types, application, and end user.
On the basis the types, it is segmented into D-phenylalanine, D-histidine, D-tyrosine, D-serine, D-alanine, D-tryptophan, D-cysteine, D-phenylglycine, D-p-hydroxy phenylglycine, D-2-chlorophenylglycine, D-penicillamine, D- proline, D-valine, D-citrulline /D-citrulene, D-lysine, D-leucine, D-glutamic acid, D-methionine, D-aspartic acid, D-arginine, D-cycloserine, and others. D-amino acids & derivatives accounted for the largest market share in 2016.
On the basis of the application, it is segmented into liver diseases, cancer, inflammatory disease, genetic diseases, and others. Liver diseases accounts for the largest market share of 32.6% in 2016.
On the basis of end user it is segmented into pharmaceutical & biotechnological companies, research laboratories, academic institutes, and others. Pharmaceutical & biotechnological companies accounts for the largest market share of 37.4% in 2016.
Key Players
The leading market players in the global unnatural amino acids market include BASF SE, Sigma-Aldrich Corporation, Novartis AG, Bayer AG, GlaxoSmithKline plc, AstraZeneca plc, Abbott Laboratories and others.
Study objectives of Unnatural Amino Acids market
• To provide insights about factors influencing and affecting the market growth
• To provide historical and forecast revenues of the market segments and sub-segments with respect to regional and country-level markets
• To provide historical and forecast revenue of the market segments based on types, products, applications, end users, and its sub-segments.
• To provide strategic profiling of key players in the market, comprehensively analyzing their market share, core competencies, and drawing a competitive landscape for the market.
Target Audience
• Pharmaceutical Companies
• Research and Development (R&D) Companies
• Government Research Institute
• Academic Institutes and Universities
• Medical Research Laboratories
• Market Research and Consulting Service Providers
• Potential Investors
Key Finding
• The global unnatural amino acids market is expected to reach USD 3,290.4 million by 2023 at a CAGR of 12.01%
• DL-amino acids & derivatives is the second largest segment, which is projected grow at a CAGR of 12.44% during the forecast period from 2017-2023
• The Americas captured the largest share of the global market and is expected to reach USD 3,290.4 million by 2023.
• Asia Pacific is the fastest growing region across the globe and is expected to grow at a CAGR of 12.16 % during the forecast period.
The reports also cover country level analysis:
• Americas
• North America
o U.S.
o Canada
• Latin America
• Europe
• Western Europe
o Germany
o France
o U.K
o Italy
o Spain
o Rest Of Western Europe
• Eastern Europe
• Asia Pacific
• Japan
• China
• India
• Republic of Korea
• Rest of Asia-Pacific
• Middle East & Africa
• Middle East
• Africa
Table of Contents:
1 Report Prologue
2 Market Introduction
2.1 Definition
2.2 Scope of Study
2.3 Research Objective
2.4 Assumptions & Limitations
2.4.1 Assumptions
2.4.2 Limitations
2.5 Market Structure
3 Research Methodology
3.1.1 Primary Research Methodology
3.1.2 Secondary Research Methodology
3.1.3 Market Share Analysis
3.1.4 Market Pricing Approach
4 Market Dynamics
4.1 Introduction
4.2 Drivers
4.2.1 Increasing application of unnatural amino acids in Pharmaceuticals (Impact Weightage 40%)
4.2.2 Increasing prevalence of chronic diseases (Impact Weightage 35%)
4.2.3 Increasing demands for new and advanced drugs (Impact Weightage 25%)
4.3 Restraints
4.3.1 Stringent Government Regulation (Impact Weightage 60%)
4.3.2 Lack of research and development sector in underdeveloped region (Impact Weightage 40%)
4.4 Opportunity
4.5 Mega Trends
4.6 Macroeconomic indicators
5 Market Factor Analysis
5.1 Value Chain Analysis
5.1.1 R&D
5.1.2 Manufacturing
5.1.3 Distribution & Sales
5.1.4 Post-sales Monitoring
5.2 Porters Five Forces Model
5.2.1 Bargaining power of suppliers (Medium to High)
5.2.2 Bargaining Power of Buyers (Low to Medium)
5.2.3 Threat of New Entrants (Low to Medium)
5.2.4 Threat of Substitutes (Medium)
5.2.5 Intensity of Rivalry (High)
5.3 Demand & Supply: Gap Analysis
5.4 Pricing Analysis
5.5 Investment Opportunity Analysis
6 Global Unnatural Amino Acids Market, by Type
6.1 Introduction
6.2 D-Amino Acids & Derivatives
6.3 DL-Amino Acids & Derivatives
6.4 β-Amino Acids & Derivatives
6.5 Cyclic Amino Acids & Derivatives
6.6 L-Amino Acid Derivatives
6.7 Gamma-Amino Butyric Acid
6.8 Gamma-Amino-Beta-Hydroxybutyric Acid
6.9 Synthetic -Amino Acids
7 Global Unnatural Amino Acids Market, by Applications
7.1 Introduction
7.2 Liver Diseases
7.3 Cancer
7.4 Inflammatory Disease
7.5 Genetic Diseases
8 Global Unnatural Amino Acids Market, By End User
8.1 Introduction
8.2 Pharmaceutical & Biotechnological Companies
8.3 Research Laboratories
8.4 Academic Institutes
9 Global Unnatural Amino Acids Market, By Region
9.1 Introduction
9.2 Americas
9.2.1 U.S.
9.2.2 Canada
9.2.3 South America
9.3 Europe
9.3.1 Germany
9.3.2 France
9.3.3 U.K
9.3.4 Italy
9.3.5 Spain
9.3.6 Rest of Western Europe
9.3.7 Eastern Europe
9.4 Asia Pacific
9.4.1 India
9.4.2 China
9.4.3 Jpan
9.4.4 Australia
9.4.5 republic of korea
9.4.6 rest of asia pacific
9.5 The Middle East and Africa
10 Competitive Landscape
10.1 Introduction
10.2 Company Share Analysis
11 Company Profiles
11.1 Aminologics Co
11.1.1 Company Overview
11.1.2 Financials
11.1.3 Products
11.1.4 Stratergy
11.1.5 Key Developments
11.2 BASF SE
11.2.1 Company Overview
11.2.2 Financials
11.2.3 Products
11.2.4 Stratergy
11.2.5 Key Developments
11.3 Sigma-Aldrich Corporation
11.3.1 Company Overview
11.3.2 Financials
11.3.3 Products
11.3.4 Stratergy
11.3.5 Key Developments
11.4 Novartis AG
11.4.1 Company Overview
11.4.2 Financials
11.4.3 Products
11.4.4 Stratergy
11.4.5 Key Developments
11.5 Bayer
11.5.1 Company Overview
11.5.2 Financials
11.5.3 Products
11.5.4 Stratergy
11.5.5 Key Developments
11.6 GlaxoSmithKline plc
11.6.1 Company Overview
11.6.2 Financials
11.6.3 Products
11.6.4 Stratergy
11.6.5 Key Developments
11.7 Abbott
11.7.1 Company Overview
11.7.2 Financials
11.7.3 Products
11.7.4 Stratergy
11.7.5 Key Developments
11.8 AstraZeneca
11.8.1 Company Overview
11.8.2 Financials
11.8.3 Products
11.8.4 Stratergy
11.8.5 Key Developments
11.9 Pfizer
11.9.1 Company Overview
11.9.2 Financials
11.9.3 Products
11.9.4 Stratergy
11.9.5 Key Developments
11.1 AbbVie
11.10.1 Company Overview
11.10.2 Financials
11.10.3 Products
11.10.4 Stratergy
11.10.5 Key Developments
11.11 Enzo-Life-Sciences , Inc
11.11.1 Company Overview
11.11.2 Financials
11.11.3 Products
11.11.4 Stratergy
11.11.5 Key Developments
11.12 CU Chemie Uetikon
11.12.1 Company Overview
11.12.2 Financials
11.12.3 Products
11.12.4 Stratergy
11.12.5 Key Developments
11.13 Yoneyama Yakuhin Kogyo
11.13.1 Company Overview
11.13.2 Financials
11.13.3 Products
11.13.4 Stratergy
11.13.5 Key Developments
11.14 Miat S.p.A.
11.14.1 Company Overview
11.14.2 Financials
11.14.3 Products
11.14.4 Stratergy
11.14.5 Key Developments
11.15 AnaSpec Inc.
11.15.1 Company Overview
11.15.2 Financials
11.15.3 Products
11.15.4 Stratergy
11.15.5 Key Developments
11.16 Ajinomoto Co., Inc.
11.16.1 Company Overview
11.16.2 Financials
11.16.3 Products
11.16.4 Stratergy
11.16.5 Key Developments
12 MRFR Conclusion
12.1 Key Findings
12.1.1 From CEO’s View Point
12.1.2 Unmet Needs
12.2 Key companies to watch
13 Appendix
13.1 Discussion Blue Print
